STOCKS TELEGRAPH

Tag: Ensysce

  • Ensysce (ENSC) Stock Sees Market Uplift Following New Patent Approval

    Ensysce (ENSC) Stock Sees Market Uplift Following New Patent Approval

    The market observed a sharp increase in Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares after the company revealed a noteworthy intellectual property milestone. The stock of ENSC was up 81.28% on the charts at $3.39 as of the most recent trading update.

    Patent Approved for Novel Treatment of Opioid Use Disorder

    Following Ensysce’s receipt of a Notice of Allowance from the U.S. invention and Trademark Office for its invention entitled “Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof,” investor confidence has surged. The formulation and method of use claims for its innovative therapeutic drug, PF9001, are covered by this patent.

    PF9001, which was created using Ensysce’s own TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance) platforms, is a novel strategy for combating the continuing opioid crisis.

    A Safer Substitute for Conventional Methadone Treatment

    Despite being commonly used to treat opioid use disorder (OUD), methadone has come under fire for probable overdose, respiratory depression, and heart problems. With its targeted release mechanism, which provides overdose protection and a consistent, once-daily dosage profile, PF9001 seeks to lessen these risks. Early data suggests a significant reduction in cardiotoxicity risks, bolstering the credibility of Ensysce’s overdose prevention technology.

    Expert Endorsement and Institutional Support

    The significance of such breakthroughs was emphasized by Dr. Richard Dart, the director of the Rocky Mountain Poison and Drug Center and a renowned expert in toxicology and emergency care. He pointed out that by lowering the risk of overdose, the use of MPAR technology with methadone analogs may save lives.

    Path Forward with Federal Backing

    Extensive research efforts to improve treatment results for OUD patients led to the creation of PF9001. The National Institute on Drug Abuse (NIDA) has acknowledged the initiative and provided funding, confirming its potential to improve public health. In the battle against opioid dependence, Ensysce (ENSC) thinks PF9001 might greatly increase patient compliance and yield better treatment outcomes.

  • After-Hour Gains For Ensysce Biosciences (ENSC) Signal Renewed Interest

    After-Hour Gains For Ensysce Biosciences (ENSC) Signal Renewed Interest

    After-hours trading on Thursday saw a partial recovery for Ensysce Biosciences, Inc. (NASDAQ: ENSC), reducing the market volatility that had been caused by a major equities release earlier in the day. In the extended session, shares of ENSC increased 7.86% to settle at $2.47 after dropping 13.26% during normal trading hours.

    New Capital via Private and Registered Offerings

    Ensysce Biosciences said that it had signed definitive agreements to generate around $1.1 million in gross revenue. ENSC will issue and sell 315,188 shares of its ordinary stock at a price of $3.49 per share through a registered direct offering priced at-the-market. In tandem, the company will conduct a private placement involving the issuance of unregistered Series A-5 and Series A-6 warrants, each allowing the purchase of up to 315,188 shares.

    At a price of $3.24 per share, the Series A-5 and A-6 warrants will be immediately exercisable. The Series A-6 warrants will be valid for five years, whilst the Series A-5 warrants will be valid for eighteen months. Depending on normal closing circumstances, the offering is anticipated to close on or around March 31, 2025. The offering’s proceeds will be used for general working capital and the advancement of Ensysce Biosciences’ exclusive TAAP and MPAR projects.

    PAINWeek 2025 Preparations

    As part of its efforts to strengthen its clinical and scientific presence, Ensysce Biosciences announced that on September 3, 2025, at PAINWeek 2025, it would host a symposium. The event’s goal is to further the discussion on pain management and the future of analgesic treatments.

    New Developments in Pain Management

    As part of the symposium preparations, ENSC recently held a panel discussion titled “The State of the Nation in Pain: A Discussion on Analgesics and Their Optimal Uses.” The panel covered new advances including Ensysce Biosciences’ PF614, a next-generation opioid, as well as the therapeutic value of presently existing analgesics and advancements in pain treatment. ENSC remains committed to collaborating with medical professionals as it creates a new class of pain treatment.